title: [Peginterferon alpha-2b in patients with chronic hepatitis C].
abstract: 150 adult patients were assigned pegylated interferon alpha-2b (once weekly 1.5 microg/kg) plus ribavirin (800-1200 mg depending on bodyweight). The treatment lasted 52 weeks and was completed by 139 persons (92.7%). Because of adverse events the treatment was interrupted in 7 persons, 4 other persons resigned. Periodical reduction of pegylated interferon doses was necessary in 19% and the reduction of ribavirin in 21% of patients. Six months after the completion of treatment HCV-RNA was negative in 82 (59%) patients. Neither hepatitis C virus genotype, nor viremia was marked in the study. The negative correlation between the degree of fibrosis in the liver tissue and the results of sustained virological response was stated. Degree of inflammation at liver tissue, sex, age over and less than 40 years did not correlate with the final virological results. The recurrence of infection happened at 7% of the treated persons (negative HCV-RNA directly after the treatment--positive 6 months after the completion). During the treatment period, and comparison with the results obtained before its implementation, statistically significantly decreased: hemoglobin concentration, the number of leukocytes, granulocytes and thrombocytes. They returned to the referential values half a year after the completion of treatment. The activity of enzymes (AIAT, AspAT, GGTP) was decreasing statistically significantly since the first weeks of the treatment till the end and remained significantly lower after 6 months. In both sexes statistically significant reduction of bodyweight was stated, while it increased during the six months after the completion of treatment. Adverse events, which mostly were mild and were not the cause of interruption of treatment, were numerous and occurred at different frequency, in the range from over 50% (flu-like) to 0.7%.
authors.affiliation: Katedra i Klinika Chorób Zakaznych AM w Poznaniu.
authors.forename: Jacek
authors.initials: J
authors.lastname: Juszczyk
authors.forename: Jolanta
authors.initials: J
authors.lastname: Białkowska
authors.forename: Beata
authors.initials: B
authors.lastname: Bolewska
authors.forename: Anna
authors.initials: A
authors.lastname: Boroń-Kaczmarska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Gładysz
authors.forename: Waldemar
authors.initials: W
authors.lastname: Halota
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Inglot
authors.forename: Urszula
authors.initials: U
authors.lastname: Janas-Skulina
authors.forename: Maciej
authors.initials: M
authors.lastname: Jabłkowski
authors.forename: Joanna
authors.initials: J
authors.lastname: Jabłonska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Jurczyk
authors.forename: Wiesław
authors.initials: W
authors.lastname: Kryczka
authors.forename: Jan
authors.initials: J
authors.lastname: Kuydowicz
authors.forename: Elzbieta A
authors.initials: EA
authors.lastname: Lakomy
authors.forename: Anna
authors.initials: A
authors.lastname: Lyczak
authors.forename: Tomasz
authors.initials: T
authors.lastname: Mach
authors.forename: Zofia
authors.initials: Z
authors.lastname: Michalska
authors.forename: Jerzy
authors.initials: J
authors.lastname: Moczko
authors.forename: Roma
authors.initials: R
authors.lastname: Modrzewska
authors.forename: Khalil
authors.initials: K
authors.lastname: Nazzal
authors.forename: Paweł
authors.initials: P
authors.lastname: Pabjan
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Pawłowska
authors.forename: Paweł
authors.initials: P
authors.lastname: Piszko
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Sikorska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Swiqtek
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Tomasiewicz
authors.forename: Ewa
authors.initials: E
authors.lastname: Topczewska-Staubach
authors.forename: Marta
authors.initials: M
authors.lastname: Wawrzynowicz-Syczewska
authors.forename: Dorota
authors.initials: D
authors.lastname: Zarqbska-Michaluk
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Zejc-Bajsarowicz
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a